This Week at the Food & Drug Administration — week of May 4, 2026

FDA had a relatively administrative week: one proposed rule about wording in its own regulations, and four final orders that move specific medical devices from the highest risk category to a lower one. None of the actions approve a product for sale or change safety standards, but together they clarify the rules manufacturers must follow.

Condoms for anal or vaginal sex get a clearer regulatory path

• FDA issued a final order classifying external condoms designed for anal or vaginal intercourse as Class II medical devices.
• The classification was requested by Global Protection Corp. to formally define how these devices are regulated.
• Why it matters: The move is mostly housekeeping. It takes condoms out of the automatic Class III category and lets future manufacturers use the standard premarket notification process instead of a full premarket approval, giving regulators a formalized safety checklist and makers a clearer route to market.

Other device reclassifications ease the burden on manufacturers

• Corneal storage medium — FDA classified corneal storage medium with preservatives including antifungals as a Class II device. The liquid temporarily preserves human cornea tissue between harvesting and implantation. It was previously treated as Class III because it wasn’t on the market before 1976. Manufacturers can now use the 510(k) process instead of the heavier premarket approval pathway, which should reduce regulatory costs and time to market while safety testing and labeling requirements stay in place.
• Circulating tumor cell enrichment devices — FDA finalized placement of these blood-testing tools, made to enrich circulating tumor cells, into Class II. The classification was finalized after a request from ANGLE Europe Ltd. for its Parsortix PC1 device. The practical effect is mostly procedural: it removes a roadblock for one device and sets a precedent that lowers the paperwork and testing burden for future competitors making the same type of tool.
• Microbiome sample preservation devices — FDA classified containers and reagents designed to preserve microbial DNA and RNA in clinical samples as Class II. Because the device type wasn’t commercially available before 1976, law had automatically put it in Class III. The change lowers the regulatory hurdle for manufacturers of microbiome collection and stabilization kits, reducing paperwork and testing requirements for the category. It does not approve any specific product.

FDA proposes swapping “gender” for “sex” in its rulebooks

• FDA published a proposed rule that would replace the word “gender” with “sex” across roughly two dozen regulations, covering drug and medical device labeling, clinical trial reporting, infant formula standards, and the composition of ethics review boards. Minor editorial tweaks for readability are also planned.
• Why it matters: This is an administrative update that aligns FDA regulations with a presidential directive. It does not change safety standards, approval processes, or compliance requirements — the practical effect is limited to the specific words used in FDA rulebooks and official guidance documents.

---

This weekly agency digest is generated from federal records (the Federal Register and Congress.gov) and summarized in plain English. It may simplify or omit detail — follow the linked official sources before relying on any item. Part of The Boring Parts.